Table 3.
Outcomes
| 30-day FU n = 646 |
1‑year FU n = 646 |
|
|---|---|---|
| CV death, MI, stroke | 6.4 | 13.6 |
| All-cause death | 4.6 | 13.0 |
| CV death | 3.4 | 6.3 |
| MI | 1.9 | 6.5 |
| ACS | 3.5 | 8.7 |
| Definite stent thrombosis | 0 | 0 |
| Probable stent thrombosis | 0.2 | 0.2 |
| TVR | 0.6 | 1.8 |
| Stroke | 0.8 | 2.0 |
| TIA | 0.2 | 0.7 |
| BARC 2 | 2.5 | 9.1 |
| BARC 3–5 | 3.3 | 5.6 |
| BARC 3 and 5 | 1.7 | 3.9 |
| BARC 2, 3 and 5 | 5.4 | 12.0 |
| Discontinuing aspirin | 3.4 | 8.7 |
| Discontinuing P2Y12 inhibitor | 4.2 | 8.8 |
All numbers are percentages
FU follow-up, CV cardiovascular, MI myocardial infarction, ACS acute coronary syndrome, TVR target vessel revascularisation, TIA transient ischaemic attack, BARC Bleeding Academic Research Consortium